10:07 AM EST - Oncolytics Biotech Inc : Reports first quarter financial results and highlights clinical momentum. Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers. An upcoming poster presentation will be at this year's ASCO Annual Meeting and will share data exhibiting pelareorep's ability to elicit innate as well as adaptive immune responses in an extremely challenging indication. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $0.71.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=5482351841842608
